Clinical Trial Update: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating polatuzumab vedotin and zanubrutinib plus R-CHP for newly diagnosed untreated diffuse large B-cell lymphoma (non-GCB subtype) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Effects of Chemotherapy, Safety Issues | Phase 2 | Status: ENROLLING_BY_INVITATION